Since 2004, Prosolia has been guided by the vision of democratizing the mass spectrometer, making the power of its measurements more accessible to scientists, clinicians and technicians. Our Desorption Electrospray Ionization (DESI) technology paved the way to achieving this vision with its invention in 2004 by a team led by Prof. R. Graham Cooks of Purdue University and included Dr. Zoltan Takats, a scientific founder, and Justin Wiseman, Prosolia’s Chairman, President & CEO. We launched our first DESI Molecular Imaging instrument in 2008 in the pharmaceutical industry and academia for a wide range of applications, including drug discovery and cancer research. In 2014, we acquired the assets of QuantIon Technologies, a Purdue Unversity spin-off, for the PaperSpray technology. We commercialized the first PaperSpray device in 2015 as the Velox 360 for drug determination applications in forensic toxicology and pharmaceuticals.
At Prosolia, we help our customers solve some of the most important problems in health and disease. We empower scientists in the pursuit of obtaining actionable molecular information for more accurate decisions in science and medicine. We do this by creating intuitive products that enhance and simplify the use of mass spectrometers, enabling new measurements, reducing complexity, and creating cost advantages for our customers to improve the outcomes for the lives we touch.
Prosolia’s platforms simplify mass spectrometry allowing direct molecular analysis for disease phenotyping and drug determination in tissue, cells and biological fluids. These platforms accelerate breakthroughs in science and medicine by helping scientists deepen their understanding of disease biology, uncover new insights into drug action and distribution, and enable new measurements.
With more made possible in the lab, what more can you discover?
Our team is comprised of life sciences entrepreneurs who share a common vision of advancing science and helping patients through innovative laboratory technology. With decades of experience in mass spectrometry, diagnostics, and bioanalytical chemistry, and backed by a world-class team of academic partners, our team is uniquely suited to accelerate clinical research and diagnostics.